Workflow
Altimmune Gears Up to Report Q2 Earnings: Here's What to Expect
AltimmuneAltimmune(US:ALT) ZACKS·2025-07-25 21:51

Key Takeaways ALT to report Q2 results with focus on pemvidutide's performance in obesity and liver disease studies.Phase IIb data showed strong MASH resolution, though fibrosis improvement lacked significance.ALT began phase II trials for ALD and AUD. Further updates are expected on the earnings call.We expect investors to focus on Altimmune’s (ALT) progress in the studies evaluating its lead pipeline candidate, pemvidutide, when it reports second-quarter 2025 results.Since ALT lacks a marketed drug in its ...